Founded in 2005, Korea Institute for Pharmaceutical Policy Affairs, KIPPA, is a non-profit, public foundation, approved by the Korean Ministry of Health and Welfare. The institute is contributed by three relevant parties, the Korean Pharmaceutical Association (KPA), the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KBPMA), and the Korea Pharmaceutical Distribution Association (KPDA).

KIPPA is a leading research center, which aims to promote public health through the development of policy regarding the rational use of medicines, pharmacy education, pharmacy practice, pharmaceutical industry, and pharmaceutical supply and distribution. In particular, we begin to develop ¡®a community pharmacy model as a health promotion center for community members¡¯. We are collecting and analysing big data accordingly to develop pharmacy-based policies, which pursue maximised pharmacy practice for all the Koreans.

In consequence, KIPPA will consistently implement research tailored to the promotion of health in the nation and worldwide. We kindly ask for supports from our fellow pharmacists, public and associations.

If you have any further enquiries about the institute or research in English, please contact us via e-mail (kippa.org@gmail.com).

Thank you.

Office Address
3FL, 194, Hyoryeong-ro, Seocho-gu, Seoul, Repbulic of Korea

ÇöÀçÀ§Ä¡ : Home : ¾Ë¸²¸¶´ç : ¿¬±¸¼Ò ´º½º
   
¾Ë¸²¸¶´ç
°øÁö»çÇ×
º¸µµÀÚ·á
ÀÎÀçä¿ë
 
 
Á¦   ¸ñ [´ëÇѾà»çÀú³Î] ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö
³»   ¿ë

¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö

¾ÈÀü»óºñÀǾàǰ ¾à±¹¿Ü ÆÇ¸ÅÁ¦µµ ¿î¿µ ÇöȲ <3>


»ç¾÷ Ã¥ÀÓÀÚ ÀÓÀ翵 ½ÇÀå
Âü¿© ¿¬±¸¿ø ±èÁøÀ̠åÀÓ¿¬±¸¿ø, Á¤½Â¿¬ ¼±ÀÓ¿¬±¸¿ø, 
                 Á¤µ¿¿í ºÎ¼±ÀÓ¿¬±¸¿ø, ÃÖÀ±Á¤ ÁÖÀÓ¿¬±¸¿ø

ÆíÁý ÀÓÀ翵 ½ÇÀå / ÀÌÁÖÇÏ ÁÖÀÓ¿¬±¸¿ø

´ëÇѾà»çȸ¿Í ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò´Â 2020³â ¾ÈÀü»óºñÀǾàǰ ÆÇ¸ÅÀÚ ±³À° °³¼±¹æ¾È ¿¬±¸¸¦ ÁøÇàÇß´Ù. º» ¿¬±¸´Â ÀǾàǰÀÇ ¾à±¹ ¿Ü ÆÇ¸Å·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö Àִ À§ÇèÀ» ÃÖ¼ÒÈ­Çϱâ À§ÇØ ¿î¿µ ÁßÀΠ¾ÈÀü»óºñÀǾàǰ ÆÇ¸ÅÀÚ ±³À°ÀÇ È¿À²¼º Á¦°í¸¦ ¸ñÀûÀ¸·Î ¼öÇàµÆ´Ù.

ÀÌ·¯ÇÑ ¸Æ¶ô¿¡¼­ º» ¿¬±¸´Â ¾ÈÀü»óºñÀǾàǰ ÆÇ¸ÅÀÚ ±³À°È¯°æÀ» Á¶»çÇϱâ À§ÇØ Çö ¾ÈÀü»óºñÀǾàǰ ¾à±¹¿Ü ÆÇ¸ÅÁ¦µµÀÇ ¿î¿µ ½ÇÅ¿͠Ÿ±¹ÀÇ ¾à±¹¿Ü ÆÇ¸ÅÁ¦µµ¸¦ Á¶»çÇß´Ù. Á¶»ç³»¿ë¿¡´Â ¾ÈÀü»óºñÀǾàǰÀÇ À¯Åë½ÇÀû(°ø±Þ¾× ±âÁØ)°ú ¾ÈÀü»óºñÀǾàǰ¿¡ ´ëÇÑ ¼ÒºñÀÚµéÀÇ ±¸¸Å °æÇè°ú ÀνÄÁ¶»ç°¡ Æ÷ÇԵƴÙ.

º» ±Û¿¡¼­´Â ¿¬±¸°úÁ¤¿¡¼­ ¾òÀº ¾ÈÀü»óºñÀǾàǰÀÇ °ø±Þ½ÇÀû°ú ¼ÒºñÀÚµéÀÇ ±¸¸Å °æÇè ¹× ÀνÄÁ¶»ç °á°ú¸¦ Åä´ë·Î ¾ÈÀü»óºñÀǾàǰ ¾à±¹¿Ü ÆÇ¸ÅÁ¦µµÀÇ ¿î¿µ ÇöȲÀ» ÆÄ¾ÇÇØº¸±â·Î ÇÑ´Ù.


<Áö³­È£¿¡ À̾>
¥². ¼ÒºñÀÚÀÇ ¾ÈÀü»óºñÀǾàǰ ±¸¸Å °æÇè°ú ÀνÄÁ¶»ç
¾ÈÀü»óºñÀǾàǰÀ» ±¸ÀÔÇÑ ¿äÀÏÀ» Á¶»çÇÑ °á°ú ÁÖ¸»(50.3%), ÁÖÁß(36.7%), ÈÞÀÏ(13%) ¼øÀ¸·Î ³ªÅ¸³µÀ¸¸ç °¡Àå ¸¹ÀÌ ±¸ÀÔÇÑ ½Ã°£´ë´Â '¿ÀÈÄ 9½Ã~ÀÚÁ¤ Àü'(37.8%), '¿ÀÈÄ 6½Ã~¿ÀÈÄ 9½Ã Àü'(34.1%)À¸·Î ÁַΠ¾à±¹ÀÌ ¹®À» ´Ý°í ³­ ÀÌÈÄ¿¡ ¾ÈÀü»óºñÀǾàǰÀ» ±¸ÀÔÇØ ´ëü·Î´Â ¾ÈÀü»óºñÀǾàǰ ÆÇ¸ÅÁ¦µµ µµÀÔ ÃëÁö¿¡ ºÎÇÕÇϴ ¾ç»óÀ» º¸ÀΠ°ÍÀ¸·Î ³ªÅ¸³µ´Ù.

ÇÏÁö¸¸ '¿ÀÀü 9½Ã~¿ÀÈÄ 6½Ã Àü'¿¡ ±¸ÀÔÇÑ ºñÀ²µµ 22.9%·Î ³·Áö´Â ¾Ê¾ÒÀ¸¸ç, ¹«¾ùº¸´Ù ÁÖÁß(¿ù~±Ý¿äÀÏ)¿¡ ±¸ÀÔÇß´ø ÀÀ´äÀڵ頰¡¿îµ¥¿¡¼­´Â '¿ÀÀü 9½Ã~¿ÀÈÄ 6½Ã Àü'¿¡ ±¸ÀÔÇÑ ÀÀ´äÀÚµµ 33.6%·Î ³ôÀº ºñÀ²À» Â÷ÁöÇß´Ù. 

Áï ¾ÈÀü»óºñÀǾàǰÀ» ±¸ÀÔÇÑ °æÇèÀÌ Àִ ¼ÒºñÀÚÀÇ °æ¿ì, ¾ÈÀü»óºñÀǾàǰ¿¡ ÇØ´çÇϴ ǰ¸ñµéÀ» ±¸ÀÔÇϴµ¥ À־ ¹Ýµå½Ã ¾à±¹À» ¹æ¹®Çϱ⺸´Ù´Â ¾à±¹°ú ÆíÀÇÁ¡ Áß ÇÑ °÷À» ¼±ÅÃÇØ¼­ ¹æ¹®Çß¾úÀ» °³¿¬¼ºÀÌ Á¸ÀçÇϴ °ÍÀ¸·Î Çؼ®ÀÌ °¡´ÉÇÏ´Ù.

±×·¸Áö¸¸ ÀÌ Á¶»çÇ׸ñÀº ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ °æÇèÀÌ Àִ ÀÀ´äÀÚ¸¸À» ´ë»óÀ¸·Î ÇßÀ¸¹Ç·Î ¾î´À Á¤µµÀÇ ÆíÇ⼺ÀÌ ¹ß»ýÇÒ ¼ö ÀÖÀ½À» Âü°íÇÒ Çʿ䰡 ÀÖ´Ù.

¾ÈÀü»óºñÀǾàǰÀ» ÆíÀÇÁ¡¿¡¼­ ±¸¸ÅÇÑ ÀÌÀ¯¸¦ ¹¯´Â Áú¹®¿¡´Â 'ÈÞÀÏ, ½É¾ß½Ã°£¿¡ ¾à±¹ÀÌ ¹®À» ´Ý¾Æ¼­'(61%), 'ÆíÀÇÁ¡ ÁÖº¯¿¡ À־ ÀÌ¿ëÇÏ±â Æí¸®ÇØ¼­'(27%), 'ÆíÀÇÁ¡¿¡¼­ ÆÇ¸ÅÇϴ ÀǾàǰÀÌ ¼ÒÆ÷ÀåÀ̾ ÀÌ¿ëÀÌ Æí¸®Çؼ­' (5%), 'ÆíÀÇÁ¡¿¡ ´Ù¸¥ ¹°°ÇÀ» »ç·¯ °¬´Ù°¡ ÇÊ¿äÇÒ °Í °°¾Æ¼­ ±¸ÀÔ' (7%) ¼øÀ¸·Î ³ôÀº ÀÀ´ä·üÀÌ ³ªÅ¸³µ´Ù.

ÀÌ·¯ÇÑ °á°ú´Â ´ëºÎºÐÀÇ »ç¶÷µéÀÌ ¾à±¹ÀÌ ¹®À» ´Ý¾Æ ¾à±¹ Á¢±Ù¼º¿¡ ¹®Á¦°¡ »ý±æ °æ¿ì ÆíÀÇÁ¡À» ¹æ¹®ÇØ ÀǾàǰÀ» ±¸ÀÔÇϴ °ÍÀ¸·Î º¼ ¼ö ÀÖ´Ù.

ÀÀ´äÀÚµéÀÌ °¡Àå ¸¹ÀÌ ±¸ÀÔÇÑ ¾àÀÇ Á¾·ù´Â ÇØ¿­ÁøÅëÁ¦(ŸÀÌ·¹³î, ¾î¸°ÀÌ¿ë Å¸ÀÌ·¹³îÇöʾ×, ¾î¸°ÀÌ¿ë ºÎ·çÆæ½Ã·´), ¼ÒÈ­Á¦(º£¾ÆÁ¦Á¤, ´ÚÅͺ£¾ÆÁ¦Á¤, ÈѽºÅ»°ñµåÁ¤, ÈѽºÅ»Ç÷¯½ºÁ¤), °¨±â¾à(ÆÇÄÝ¿¡À̳»º¹¾×, ÆÄÇǸ°Æ¼Á¤), ÆÄ½º(Á¦ÀÏÄðÆÄÇÁ, ½Å½ÅÆÄ½º¾Æ·º½º) ¼øÀ¸·Î ³ªÅ¸³µ´Ù.

ÆíÀÇÁ¡¿¡¼­ ¾ÈÀü»óºñÀǾàǰÀ» ±¸ÀÔÇÏÁö ¾ÊÀº ÀÌÀ¯¿¡ ´ëÇØ ÀÀ´äÀڴ '¾àÀ» º¹¿ëÇÒ ÀÏÀÌ ¾ø¾î¼­', 'Æò¼Ò¿¡ ÇÊ¿äÇÑ ÀǾàǰÀ» °¡Á¤¿¡ ±¸ºñÇØ µÎ¾î µû·Î ±¸ÀÔÇÒ Çʿ䰡 ¾ø¾î¼­'¶ó´Â Ç׸ñÀ» °¡Àå ºó¹øÇϰԠ¼±ÅÃÇß´Ù. 

±×·¸Áö¸¸ 'ÆíÀÇÁ¡¿¡´Â Áõ»ó¿¡ ¸Â´Â ¾àÀÌ ¾ø¾î¼­', '¾à±¹¿¡¼­ ±¸ÀÔÇϴ °Íº¸´Ù °¡°ÝÀÌ ºñ½Î¼­' µîÀÇ Ç׸ñµµ ÀûÁö ¾ÊÀº ¼ÒºñÀÚ°¡ ÀÀ´äÇÑ °ÍÀ¸·Î ³ªÅ¸³ª ¾ÈÀü»óºñÀǾàǰ ¹Ì±¸ÀÔÀÚÀÇ °æ¿ì ÀǾàǰ ±¸¸Åó·Î¼­ÀÇ ¾à±¹°ú ÆíÀÇÁ¡ÀǠƯ¼º¿¡ ´ëÇØ ÀνÄÇϰí ÀÖÀ¸¸ç ÀÌ·¯ÇÑ ÀνÄÀÌ ¹Ì±¸ÀÔ ÀÇ»ç°áÁ¤¿¡ ¿µÇâÀ» ¹ÌÃÆÀ» °³¿¬¼ºÀÌ ÀÖÀ½À» ¾Ë ¼ö ÀÖ´Ù<±×¸²2>.


[±â»çÃâó] https://www.kpanews.co.kr/academy/show.asp?page=1&search_cate=8&idx=668


 

¹øÈ£ ÷ºÎ Á¦¸ñ ÀÛ¼ºÀÚ ÀÛ¼ºÀÏ Á¶È¸
129 [´ëÇѾà»çÀú³Î]°ø°ø½É¾ß¾à±¹, »ç¾÷ È®´ë À§ÇØ ¿î¿µ¡¤ÆíÀÇ °³¼± ÇÊ¿ä ÀÌÁÖÇÏ 2021-09-23 900
128 [´ëÇѾà»çÀú³Î]½É¾ß½Ã°£ ¾à±¹ ÀÌ¿ë '¸¸Á·ÇÑ´Ù' 93.5% ÀÌÁÖÇÏ 2021-09-23 780
127 [´ëÇѾà»çÀú³Î]¿µ±¹, OHH ¼­ºñ½º ÀϹݾࡤÀü¹®¾à ³ª´² Á¦°ø ÀÌÁÖÇÏ 2021-09-23 758
126 [´ëÇѾà»çÀú³Î]È£ÁÖ ¹ãÀ» ¹àÈ÷´Â 'Supercare' ¾à±¹ ÀÌÁÖÇÏ 2021-09-23 764
125 [ÀǾàǰÁ¤Ã¥¸®Æ÷Æ®]ÀÀ´äÀÚ 94.3% µµÀÔ Âù¼º¡¦Àü¹®Àû »ó´ã Àý½Ç ÀÌÁÖÇÏ 2021-09-23 250
124 [´ëÇѾà»çÀú³Î] ¾à ±¸ÀÔ ½Ã ¾à»ç¿Í »ó´ãÀÌ Áß¿ä 85% ÀÌÁö¿¬ 2021-08-10 520
123 [´ëÇѾà»çÀú³Î] ÀǾàǰ ¾ÈÀü»ç¿ë ±³À° 'µµ¿òµÆ´Ù' 98% ÀÌÁö¿¬ 2021-08-02 460
122 [´ëÇѾà»çÀú³Î] ¾ÆÆí ÇÔÀ¯ 'Á¤ÅëÆí' ÅëÁõ ¸¸º´ÅëÄ¡¾àó·³ »ç¿ë ÀÌÁö¿¬ 2021-08-02 506
121 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠó¹æÀǾàǰ È¿°ú ½Å·Ú ´õ ³ô¾Æ ÀÌÁö¿¬ 2021-07-21 448
120 [´ëÇѾà»çÀú³Î] ºÏÇÑÀÌÅ»ÁֹΠÀǾàǰ Àνİú »ç¿ë ÇöȲÀº? ÀÌÁö¿¬ 2021-07-14 390
119 [´ëÇѾà»çÀú³Î] "ºÎÀÛ¿ë °æÇè 98% Áõ»ó ½Å°í¾ÈÇØ" ºÒ°¨Áõ ½É°¢ ÀÌÁö¿¬ 2021-07-07 464
118 [´ëÇѾà»çÀú³Î] ¾ÈÀü»óºñÀǾàǰ ±¸ÀÔ ¿äÀÏ ÁÖ¸» '50.3%' Â÷Áö ÀÌÁö¿¬ 2021-06-29 453
117 [´ëÇѾà»çÀú³Î] ±¹¹Î 90% 1³â°£ ÆíÀÇÁ¡ »óºñ¾à ÃÖ´ë 5ȸ ±¸ÀÔ ÀÌÁö¿¬ 2021-06-22 486
116 [´ëÇѾà»çÀú³Î] ÆíÀÇÁ¡ ºøÀå Ç®¸®ÀÚ ½ñ¾ÆÁø °¨±â¾à¡¤ÁøÅëÁ¦ ÀÌÁö¿¬ 2021-06-16 433
115 [´ëÇѾà»çÀú³Î] Áö¿ª¾à±¹ '»ý¸íÁöÅ´ÀÌ' ¿ªÇÒ ¼öÇà °ü½É ³ôÇû´Ù ÀÌÁö¿¬ 2021-06-09 441

ÀÌÀü 10ÆäÀÌÁö [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8]  [9]  ´ÙÀ½ 10ÆäÀÌÁö

 
 

¼­¿ï ¼­Ãʱ¸ È¿·É·Î194, 3Ãþ (Àç)ÀǾàǰÁ¤Ã¥¿¬±¸¼Ò TEL : 02) 3474-5301 / FAX : 02)3474-5306

COPYRIGHT (C) 2006 KOREA INSTITUTE FOR PHARMACEUTICAL POLICY AFFAIRS ALL RIGHTS RESERVED. FOR MORE INFORMATION MAL kippa.org@gmail.com

±âºÎ±Ý ¾È³»